Newstral
Marc Goodman
- M5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners4 min readmarketwatch.com
- MFDA approves new ALS drug that costs $158,000 a year2 min readmarketwatch.com
- MWill Medicare cover Eisai and Biogen's promising new Alzheimer's therapy if it's approved?3 min readmarketwatch.com
- BIt's Lights Out for Biogen's Aduhelm4 min readbarrons.com
- MBiogen's new Alzheimer's treatment had 'potentially the worst drug launch of all time,' analyst says3 min readmarketwatch.com
- BAcknowledging Concerns Over Biogen's Alzheimer's Drug, FDA Asks for Investigation2 min readbarrons.com
- BBiogen’s Alzheimer’s Drug Opens Up a New Market. These Stocks Could Benefit.4 minbarrons.com
- BBiogen Stock Jumps on FDA Approvalbarrons.com
- BBiogen's Alzheimer's Drug Is Approved by the FDAbarrons.com
- Maine abandons fight for law requiring à la carte cable TV servicepressherald.com
- MBiogen talks up approval plans for controversial Alzheimer's drug as it nears FDA decisionmarketwatch.com
- BProgress in Alzheimer’s Drug Development Still Gives Reasons to Hopebarrons.com
- MGW Pharma shares slide 12% after company swings to loss during pandemicmarketwatch.com
- MGW Pharma's stock rallies after its cannabinoid drug gets a new FDA approvalmarketwatch.com
- MZogenix's shares rise on FDA approval of seizure drugmarketwatch.com
- BAlkermes Reported More Revenue Than Expected. Here’s Why the Stock Is Falling.barrons.com
- MInvestors flock to psychiatric treatments after FDA approves new schizophrenia drugmarketwatch.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.